What is optimal in patients with myasthenic crisis: Invasive or non-invasive ventilation?

Hemant Bhagat, Vinod K. Grover, Kiran Jangra

Abstract

Myasthenia gravis is an immune disorder involving the neuromuscular junction. The consequent weakness of respiratory muscles leads to variable disorders of ventilation in patients with myasthenia gravis. This article reviews the options of invasive and non-invasive ventilation in patients with advanced form of the disease.

Key words: Invasive ventilation, myasthenia gravis, non-invasive ventilation

INTRODUCTION

Myasthenia gravis (MG) is an immunological neuromuscular disorder, characterized by fluctuating weakness and fatigability of skeletal muscles. There is an antibody-mediated autoimmune attack at the post-synaptic membrane of the neuromuscular junction leading to (a) reduction of acetylcholine receptors and (b) flattening of post-synaptic clefts. There is also a reduction in the amount of acetylcholine release with repeated activity (presynaptic rundown). These result in decreased efficiency of neuromuscular transmission with consequent weakness of muscle contraction.

The prevalence of MG is 0.5-12.5 per 10,000 population and incidence is 0.4 per 10,000 with a female preponderance. The myasthenic weakness increases with repeated use (fatigue) and improves with rest or sleep. Exacerbations and remissions may occur, though remissions are rarely complete or permanent. The morbidity and mortality is usually high in critically ill patients. The course of the disease is variable and mortality in early 1960s was as high as 40%. Over the subsequent decades, there was improvement in specialized neurological intensive care unit (ICU) and the mortality reduced to 4-6%.

The features that best describe the myasthenia gravis include involvement of ocular and proximal muscles, usually asymmetric, no loss of sensation/neurological function/deep tendon reflexes. The diagnosis is confirmed by clinical response to cholinergic drugs (edrophonium or neostigmine test), electrodiagnostic studies and the presence of serum antibodies against acetylcholine receptors. The severity of clinical illness is best described by a modified Osserman classification [Table 1]. The pathophysiological changes following muscle

<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Patients with ocular involvement alone</td>
</tr>
<tr>
<td>II</td>
<td>Mild muscular weakness, not incapacitating</td>
</tr>
<tr>
<td>III</td>
<td>Moderate muscular weakness, not incapacitating, including oropharyngeal and respiratory muscle weakness</td>
</tr>
<tr>
<td>IV</td>
<td>Incapacitating weakness of any muscle system, including oropharyngeal and respiratory muscle weakness</td>
</tr>
<tr>
<td>V</td>
<td>Life-threatening respiratory insufficiency requiring ventilatory assistance (crisis)</td>
</tr>
</tbody>
</table>

Table 1: Modified Osserman classification

Access this article online

Website: www.jnaccjournal.org

DOI: 10.4103/2348-0548.130388

Address for correspondence:
Dr. Hemant Bhagat, Department of Anaesthesia and Intensive Care, Postgraduate Institute of Medical Education and Research, Chandigarh - 160 012, India. E-mail: drhemantbhagat@rediffmail.com

Department of Anaesthesia and Intensive Care, Postgraduate Institute of Medical Education and Research, Chandigarh, India
weakness and the consequent clinical effects have been schematically presented in Figure 1.[10]

A critical care specialist may be expected to treat severely ill myasthenic patients in class 4 or 5 [Table 1]. These groups of patients are best managed in a specialized neurointensive care unit (NICU). Evaluation of critically ill myasthenic patients is very important to differentiate between the ones which have incapacitating oropharyngeal and respiratory muscle weakness (MG class IV, impending crisis) and the ones that are in respiratory failure (MG Class V, myasthenic crisis). The clinical signs and symptoms between the two classes are overlapping and probably the most important objective criteria to differentiate between Class IV and Class V MG would be (a) vital capacity (VC) and (b) arterial blood gas analysis.[11]

The simplest and the most reliable way to determine impending respiratory failure is by frequent use of bedside measurements of VC by handheld spirometer.[11] A normal VC is approximately 55-65 ml/kg depending on age, body size and pre-existing respiratory disease. A reduction to 30 ml/kg is associated with poor cough and accumulation of oropharyngeal secretions. At the level of 25 ml/kg sigh mechanism are impaired and atelectasis develops which may result in mild hypoxaemia. If VC falls below 15 ml/kg, respiratory failure ensues for which elective intubation is usually necessary to support ventilation so as to allow O₂ exchange and prevent muscle fatigue. Arterial blood gas analysis is another important parameter to demonstrate respiratory failure. PaO₂ less than 60 mmHg or PaCO₂ more than 50 mmHg unequivocally diagnoses respiratory failure.[11]

The prognosis of MG has drastically improved as a result of advances in treatment modalities. Virtually, all myasthenic patients can be returned to productive lives with rational therapy, which includes judicious use of anticholinesterase medications, immunosuppressive agents, thymectomy, plasmapheresis, intravenous immunoglobulins (IVIg) and advanced respiratory care.[11]

There are two important issues in the management of critically ill myasthenic patients. The first is the need for airway protection and second is the need for mechanical ventilation. The literature clearly supports the conventional technique of intubation and mechanical ventilation to overcome these issues. The use of non-invasive ventilation is in a stage of evolution as far as respiratory management is concerned in myasthenic patients. Various aspects of invasive and non-invasive ventilation are discussed below.

**INVASIVE VENTILATION**

The use of ventilatory support in a patient via a definitive airway/invasive conduit is referred to as invasive ventilation. The invasive ventilation can be used via following airways[11,12]

1. Endotracheal tube
2. Tracheostomy tube

Advantages and disadvantages of invasive ventilation are tabulated in Tables 2 and 3.[13]

![Figure 1: Pathophysiological effects of respiratory muscle weakness](image)

**Table 2: Advantages of invasive ventilation**

| Early ventilation support is an option (in patients with class IV MG) |
| Intermittent ventilation is possible |
| Ventilation outside ICU is possible |
| Patients can eat/drink |
| Communication is possible |
| Patient can cooperate for physiotherapy |
| Avoids intubation |
| Reduces ICU/hospital stay |

ICU = intensive care unit, MG = myasthenia gravis

**Table 3: Disadvantages of invasive ventilation**

| Complications related to process of intubation |
| Complications due to ventilation |
| Loss of airway defense mechanism |
| Complications related to removal of endotracheal/tracheostomy tube |
Endotracheal intubation carries well-known risks of complications. These fall into three main categories: complications directly related to the process of intubation and mechanical ventilation, those caused by the loss of airway defense mechanisms, and those that occur after removal of the endotracheal tube.

The first category includes aspiration of gastric contents, trauma to the teeth, hypopharynx, esophagus, larynx, and trachea, arrhythmias, hypotension, and barotrauma that may occur during placement of a translaryngeal tube. With tracheostomy placement, risks include hemorrhage, stomal infection, intubation of a false lumen, mediastinitis, and acute injury to the trachea and surrounding structures, including the esophagus and blood vessels.

In the second and third category, endotracheal tube provides a direct conduit to the lower airways for microorganisms and other foreign materials, permitting chronic bacterial colonization, inflammation, and impairment of airway ciliary function.

The last category includes hoarseness, sore throat, cough, sputum production, and hemoptysis. Upper airway obstruction caused by vocal cord dysfunction or laryngeal swelling, and tracheal stenosis may follow extubation.

**Evidence for use**

The conventional and popular mode of ventilation in myasthenic patients has been ventilator support via an endotracheal tube, tracheostomy and minitracheostomy. Tracheostomy is considered if patients requires airway protection/mechanical ventilation for more than 2 weeks. The evidence for use of invasive ventilation is strong and has been recommended in most of the series published so far. The mortality in the patients receiving invasive ventilation has been as low as 4-6%.

In an unpublished data from a tertiary care neurological ICU in India, 59 patients with 74 episodes of myasthenic crisis were studied. The patients were intubated endotracheally and mechanically ventilated for median duration of 11 days. In 22.9% of episodes of crisis, tracheostomy was required. The outcome in terms of mortality (6.7%) was comparable to most of the centers worldwide.

In another Indian study, where 23 episodes of myasthenia gravis were studied the median duration of crisis episode was 11 days. These patients were intubated and mechanically ventilated. Two (8%) of the 23 episodes were fatal, one resulting from ventilator-associated pneumonia and another due to crisis itself.

**NON-INVASIVE VENTILATION**

Non-invasive ventilation (NIV) refers to the delivery of mechanical ventilation using techniques that do not require a definitive airway. During non-invasive positive pressure ventilation, the gas is delivered to the airway via a mask or a relevant interface. The open breathing circuit of NIV causes air leak around the mask, rendering its success to be critically dependent on ventilator system designed to deal effectively with air leaks and to optimize patients comfort and acceptance.

The following interfaces are used for delivery of non-invasive ventilation:
1. Nasal masks
2. Oro-nasal masks
3. Mouth pieces

The ventilator modes that can be used are –
1. Continuous positive airway pressure (CPAP).
2. Pressure-limited ventilators
   a. Pressure Support Ventilation (PSV)
   b. Pressure-Controlled Ventilation (PCV)
   c. Bi-level Positive Airway Pressure (BIPAP)
3. Volume-limited ventilators
4. Proportional assist ventilation—targets patient’s efforts rather than pressure or volume.

Advantages and disadvantages of non-invasive ventilation are tabulated in Tables 4 and 5.

**Table 4: Advantages of non-invasive ventilation**

<table>
<thead>
<tr>
<th>Advantage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early ventilation support is an option (in patients with class IV MG)</td>
</tr>
<tr>
<td>Intermittent ventilation is possible</td>
</tr>
<tr>
<td>Ventilation outside ICU is possible</td>
</tr>
<tr>
<td>Patients can eat/drink</td>
</tr>
<tr>
<td>Communication is possible</td>
</tr>
<tr>
<td>Patient can cooperate for physiotherapy</td>
</tr>
<tr>
<td>Avoids intubation</td>
</tr>
<tr>
<td>Reduces ICU/hospital stay</td>
</tr>
</tbody>
</table>

**Table 5: Disadvantages of non-invasive ventilation**

<table>
<thead>
<tr>
<th>Disadvantage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Airway is not protected, which is a major concern in myasthenic patients</td>
</tr>
<tr>
<td>No direct access to bronchial tree for suctioning of secretions (another concern in patients on optimal dose of anti-cholinesterases)</td>
</tr>
<tr>
<td>Efficacy for management of patient in myasthenia crisis is yet to be proven</td>
</tr>
<tr>
<td>Mask uncomfortable/claustrophobic (the patient may not be able to adjust the mask due to weakness and is totally dependent on others)</td>
</tr>
<tr>
<td>Facial pressure sores</td>
</tr>
<tr>
<td>Drug holiday may not be possible</td>
</tr>
</tbody>
</table>
Evidence for use

There have been reports of the successful use of non-invasive ventilation in patients with MG.\textsuperscript{17,18} NIV can be especially useful in the management of myasthenic crisis. Although some previous studies concluded that early intubation for mechanical ventilation is an important step in the management of these patients. Other reports suggested that NIV could prevent intubation in myasthenia gravis patients with respiratory failure.\textsuperscript{16,19} In a recent study reported by Seneviratne et al., NIV was the initial ventilator support in 24 episodes of myasthenic crisis and intubation was prevented in 14 episodes.\textsuperscript{18} In that study severe hypercapnia (\(\text{PaCO}_2 > 45\) mmHg) was a predictor of NIV failure. In another study NIV was recommended in myasthenia gravis if serum bicarbonate concentration was below 30 mmol/L\textsuperscript{20} and APACHE II Score was less than 6. In this study authors recommend serum bicarbonate is superior to \(\text{PaCO}_2\) in predicting NIV failure. None of the patients in this study had renal failure when admitted to ICU. The initial serum level of bicarbonate might be a better indicator of severity and chronicity of the respiratory acidosis and thereby the capacity of respiratory muscles. Patients in this study were more hypercapnic than the patients in the study conducted by Seneviratne et al.

Jenn-Yu Wu et al., have also analyzed NIV application after extubation.\textsuperscript{20} Intermittent NIV support was applied to 10 (30.3\%) out of 33 patients undergoing mechanical ventilation after extubation. Seven of them received NIV support \(<6\) h/day and were successfully prevented from reintubation. The other 3 (30\%) patients became NIV dependent immediately after extubation and were reintubated.

The experience of our institute is limited. However, the successful use of BIPAP in one patient who had hypercapnic respiratory failure has been reported.\textsuperscript{21} In an interesting case report, a 12-year-old girl suffering from seronegative MG was treated with helmet delivered NIV during recurrent myasthenic episodes. Never the less in one episode she had bronchopneumonia for which she had to be shifted to invasive approach.

In face of available evidence in support of non-invasive ventilation for exacerbation of MG, the findings of various studies and case reports probably generate a hypothesis that non-invasive ventilation may be a good option of ventilatory management in myasthenic patients with respiratory impairment and also may be useful in post-extubation period in patients who initially were intubated and mechanically ventilated.

CONCLUSIONS

1. The conventional endotracheal intubation and mechanical ventilation is still the gold standard for management of myasthenia crisis (MG Class V)
2. The use of non-invasive ventilation may be useful in managing patients with incapacitating respiratory muscle weakness (MG Class IV) and preventing the use of invasive ventilation
3. Initiation of BIPAP ventilation may be associated with shorter duration of ventilation as well as ICU and hospital stay
4. Arterial carbon-dioxide (\(\text{PaCO}_2\)) levels greater than 45 mmHg on BIPAP, is one of the indicators for failure of BIPAP ventilation in myasthenia patients.

REFERENCES


How to cite this article: Bhagat H, Grover VK, Jangra K. What is optimal in patients with myasthenic crisis: Invasive or non-invasive ventilation?. J Neuroanaesthesiol Crit Care 2014;1:116-20.

Source of Support: Nil, Conflict of Interest: None declared.